Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma

Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma

Background: Most data on autologous hematopoietic cell transplantation (auto-HCT) in myeloma are based on the use of innovator formulation of melphalan. Comparative bioequivalence and efficacy studies of generic melphalan are lacking. Methods: In this retrospective study, we report long-term outcome...

Full description

Bibliographic Details
Main Authors: Deepesh P. Lad, Pankaj Malhotra, Amol N. Patil, Ram V. Nampoothiri, Kripa Shanker Kasudhan, Alka Khadwal, Gaurav Prakash, Arihant Jain, Samir Malhotra, Neelam Varma, Savita Verma Attri, Subhash Varma
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Hematology/Oncology and Stem Cell Therapy
Subjects:
Auto-HCT
Generic
Innovator
Melphalan
Myeloma
Online Access:http://www.sciencedirect.com/science/article/pii/S1658387620301138

Internet

http://www.sciencedirect.com/science/article/pii/S1658387620301138

Similar Items